Targeting cellular pathways in glioblastoma multiforme
Joshua R D Pearson1, Tarik Regad1
1The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Lane, Nottingham, UK.
Abstract:
Glioblastoma multiforme (GBM) is a debilitating disease that is associated with poor prognosis, short median patient survival and a very limited response to therapies. GBM has a very complex pathogenesis that involves mutations and alterations of several key cellular pathways that are involved in cell proliferation, survival, migration and angiogenesis. Therefore, efforts that are directed toward better understanding of GBM pathogenesis are essential to the development of efficient therapies that provide hope and extent patient survival. In this review, we outline the alterations commonly associated with GBM pathogenesis and summarize therapeutic strategies that are aimed at targeting aberrant cellular pathways in GBM.
Insights
Glioblastoma multiforme (GBM) is a deadly brain cancer with poor outcomes. Understanding its complex cellular pathway alterations is key to developing effective glioblastoma treatments and improving patient survival.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Glioblastoma multiforme (GBM) presents a significant clinical challenge due to its aggressive nature, poor prognosis, and limited therapeutic responses.
- The pathogenesis of GBM is intricate, involving dysregulation of critical cellular pathways such as proliferation, survival, migration, and angiogenesis.
- A deeper comprehension of GBM's molecular underpinnings is crucial for advancing treatment strategies.
Purpose of the Study:
- To review the common molecular alterations implicated in glioblastoma multiforme pathogenesis.
- To summarize current and emerging therapeutic strategies targeting aberrant cellular pathways in GBM.
- To provide insights into developing more effective treatments for glioblastoma.
Main Methods:
- Comprehensive literature review of studies on glioblastoma pathogenesis.
- Analysis of key cellular pathways frequently altered in GBM.
- Synthesis of information on therapeutic interventions targeting these pathways.
Main Results:
- Identification of frequently mutated and altered cellular pathways in GBM.
- Overview of therapeutic approaches including targeted therapies and pathway inhibitors.
- Highlighting the link between specific molecular alterations and treatment responses.
Conclusions:
- Targeting aberrant cellular pathways in GBM holds promise for improving therapeutic efficacy.
- Continued research into GBM molecular pathogenesis is essential for developing novel and effective treatments.
- Enhanced understanding can lead to improved patient survival and quality of life for glioblastoma patients.
